Related Experiment Videos
Cytotoxic chemotherapy for advanced renal cell carcinoma
A Yagoda1, D Petrylak, S Thompson
1Medical Oncology Division, Columbia-Presbyterian Medical Center, New York, New York.
The Urologic Clinics of North America
|May 1, 1993
Summary
This review of 72 chemotherapy drugs found minimal effectiveness against renal cell carcinoma. Objective response rates were only 5.6% in over 3500 patients, indicating this cancer is highly resistant to chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) is a complex malignancy.
- Chemotherapy is a cornerstone of cancer treatment, but its efficacy varies significantly across tumor types.
Purpose of the Study:
- To evaluate the objective response rates of cytotoxic chemotherapeutic agents in patients with renal cell carcinoma.
- To determine the overall efficacy of single-agent and limited two-drug combination chemotherapy for advanced RCC.
Main Methods:
- Systematic review and analysis of data from 3502 adequately treated patients.
- Inclusion of 72 cytotoxic chemotherapeutic agents, used alone or in two-drug combinations.
- Objective response assessment based on complete and partial remission rates.
Main Results:
- An overall objective response rate of 5.6% (197/3502 patients) was observed.
- Confidence interval for the response rate was 4.8% to 6.4%.
- The majority of evaluated chemotherapeutic agents demonstrated limited efficacy.
Conclusions:
- Renal cell carcinoma exhibits significant resistance to currently available cytotoxic chemotherapeutic agents.
- While some agents may warrant further investigation, chemotherapy is not a primary effective treatment for RCC at this time.
- Further research into novel therapeutic strategies for RCC is crucial.